Roles of chemokine receptor CX3CR1 in maintaining murine bone homeostasis through the regulation of both osteoblasts and osteoclasts

Summary Chemokines have recently been reported to be involved in pathological bone destruction. However, the physiological roles of chemokines in bone metabolism in vivo have not been well documented. We analyzed the bone phenotypes in Cx3cr1-deficient mice. The mice exhibited slight but significant increases in trabecular and cortical thickness, reduced numbers of osteoclasts and increased rates of osteoid formation. Although the morphometric parameters showed marginal differences, the Cx3cr1-deficient bones showed an elevated expression of Osterix/SP7, which encodes an essential transcriptional factor for osteoblasts, whereas the gene Osteocalcin/Bglap, which encodes a late marker, was downregulated. The levels of transcripts for various osteoclastic markers, such as receptor activator of NF-&kgr;B (RANK)/TNFRSF11A, receptor activator of NF-&kgr;B ligand (RANKL)/TNFSF11, tartrate-resistant acid phosphatase 5b (TRAP5B)/ACP5B, Cathepsin K(CTSK), MMP3 and MMP13, were significantly decreased in the Cx3cr1-deficient bones. Cultured Cx3cr1-deficient osteoblastic cells showed inverse temporal patterns of osteoblastic marker expression and reduced calcium deposition. Furthermore, in vitro studies and immunofluorescence staining against CX3CR1 and CX3CL1 suggested a role for the CX3CR1–CX3CL1 axis in an early stage of osteoblast differentiation, possibly through their trans and cis interactions. Cultured Cx3cr1-deficient pre-osteoclasts showed impaired differentiation, mainly due to a deficiency of the CD115+CD11blo osteoclastogenic population of myeloid-lineage precursors. The treatment of bone-marrow-derived osteoclastic cultures with recombinant CX3CL1 at different time points suggested that the CX3CR1–CX3CL1 axis favors the maintenance of osteoclastic precursors, but not differentiated osteoclasts. These observations uncovered novel roles of the CX3CR1–CX3CL1 axis in the differentiation of both osteoblasts and osteoclasts.

[1]  A. Yamaguchi,et al.  Increasing participation of sclerostin in postnatal bone development, revealed by three-dimensional immunofluorescence morphometry. , 2012, Bone.

[2]  K. Yamana,et al.  SP7 Inhibits Osteoblast Differentiation at a Late Stage in Mice , 2012, PloS one.

[3]  K. Matsushima,et al.  Deficiency of Chemokine Receptor CCR1 Causes Osteopenia Due to Impaired Functions of Osteoclasts and Osteoblasts* , 2010, The Journal of Biological Chemistry.

[4]  K. Tsuneyama,et al.  Role of CX3CL1/Fractalkine in Osteoclast Differentiation and Bone Resorption1 , 2009, The Journal of Immunology.

[5]  H. Takayanagi,et al.  Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis , 2009, Nature Medicine.

[6]  M. Mack,et al.  Estrogen-dependent and C-C chemokine receptor-2–dependent pathways determine osteoclast behavior in osteoporosis , 2009, Nature Medicine.

[7]  J. Bernhagen,et al.  Macrophage migration inhibitory factor: a noncanonical chemokine important in atherosclerosis. , 2009, Trends in cardiovascular medicine.

[8]  M. Ishii,et al.  Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis , 2009, Nature.

[9]  A. Ludwig,et al.  Glial cross-talk by transmembrane chemokines CX3CL1 and CXCL16 , 2008, Journal of Neuroimmunology.

[10]  Y. Sheikine,et al.  CXCL16/SR-PSOX--a friend or a foe in atherosclerosis? , 2008, Atherosclerosis.

[11]  H. Sakurai,et al.  RANKL-induced down-regulation of CX3CR1 via PI3K/Akt signaling pathway suppresses Fractalkine/CX3CL1-induced cellular responses in RAW264.7 cells. , 2007, Biochemical and biophysical research communications.

[12]  M. Suematsu,et al.  Critical Role for CXC Chemokine Ligand 16 (SR-PSOX) in Th1 Response Mediated by NKT Cells1 , 2007, The Journal of Immunology.

[13]  L. Qin,et al.  Parathyroid Hormone Stimulates Osteoblastic Expression of MCP-1 to Recruit and Increase the Fusion of Pre/Osteoclasts* , 2007, Journal of Biological Chemistry.

[14]  P. Croucher,et al.  Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model , 2006, Clinical & Experimental Metastasis.

[15]  K. Yamana,et al.  Cbfβ regulates Runx2 function isoform-dependently in postnatal bone development , 2006 .

[16]  J. Aubin,et al.  Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. , 2006, Blood.

[17]  N. Morrison,et al.  Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP‐1 and RANTES , 2006, Journal of cellular biochemistry.

[18]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[19]  Hajime Orimo,et al.  Multi‐Detector Row CT Imaging of Vertebral Microstructure for Evaluation of Fracture Risk , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  W. Han,et al.  Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4) , 2005, Life Sciences.

[21]  P. Tak,et al.  Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis , 2005, Annals of the rheumatic diseases.

[22]  N. Callander,et al.  MIP-1α utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells , 2005 .

[23]  Hidde L Ploegh,et al.  CX3CR1-Mediated Dendritic Cell Access to the Intestinal Lumen and Bacterial Clearance , 2005, Science.

[24]  T. Kita,et al.  Cell surface‐anchored SR‐PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6‐expressing cells , 2004, Journal of leukocyte biology.

[25]  M. de Virgilio,et al.  The nuclear protein HMGB1, a new kind of chemokine? , 2003, FEBS letters.

[26]  Yingyu Chen,et al.  Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. , 2003, Genomics.

[27]  J. Deng,et al.  The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation , 2002, Cell.

[28]  N. Kanatani,et al.  Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures , 2001, The Journal of cell biology.

[29]  G. Roodman,et al.  Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. , 2001, Blood.

[30]  T. Miyata,et al.  Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.

[31]  P. Rüegsegger,et al.  Direct Three‐Dimensional Morphometric Analysis of Human Cancellous Bone: Microstructural Data from Spine, Femur, Iliac Crest, and Calcaneus , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  S B Rosalki,et al.  BIOCHEMICAL MARKERS OF BONE TURNOVER , 1998, International journal of clinical practice.

[33]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[34]  E. Barrett-Connor,et al.  Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. , 1997, Archives of internal medicine.

[35]  Makoto Sato,et al.  Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.

[36]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[37]  T. Ohishi,et al.  Evaluation of bone turnover in postmenopause, vertebral fracture, and hip fracture using biochemical markers for bone formation and resorption , 1997, Journal of endocrinological investigation.

[38]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[39]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  K. Yamana,et al.  Cbf beta regulates Runx2 function isoform-dependently in postnatal bone development. , 2006, Developmental biology.

[41]  N. Callander,et al.  MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. , 2005, Experimental hematology.

[42]  G. Roodman,et al.  Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. , 2001, Blood.

[43]  F. Craig,et al.  Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. , 2000, Blood.